Mark Yarchoan

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 47

Top Topics

Regulatory T Cells

Top Venues

Cancer research communications

Nature medicine

Nature reviews. Clinical oncology

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Josep M Llovet, Roser Pinyol, Mark Yarchoan, Amit G Singal, Thomas U Marron, Myron E Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S Finn
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature reviews. Clinical oncology (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine 30 (4) (2024)
Josep M Llovet, Roser Pinyol, Mark Yarchoan, Amit G Singal, Thomas U Marron, Myron E Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S Finn
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature reviews. Clinical oncology 21 (4) (2024)
Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith, Robert A Anders, Kiyoko Oshima, Amy K Kim, Jacqueline Laurin, Kelly J Lafaro, Christopher R Shubert, William R Burns, Jin He, Richard Andrew Burkhart, Benjamin Philosophe, Jeffrey Meyer, Robert P Liddell, Christos S Georgiades, Kelvin Hong, Won Jin Ho, Nilofer S Azad, Alexandra T Strauss, Mark Yarchoan
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC. Cancer research communications 4 (8) (2024)
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, Eliza Wright Beal, Richard S Finn, Terence P F Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi P Jhawer, Asha Karippot, Ahmed Omar Kaseb, Robin Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M Remak, Davendra P S Sohal, Tamar Hamosh Taddei, Andrea Wilson Woods, Mark Yarchoan, Michal G Rose
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine 30 (4) (2024)
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, Eliza Wright Beal, Richard S Finn, Terence P F Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi P Jhawer, Asha Karippot, Ahmed Omar Kaseb, Robin Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M Remak, Davendra P S Sohal, Tamar Hamosh Taddei, Andrea Wilson Woods, Mark Yarchoan, Nicholas G Zaorsky
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Amit G Singal, Mark Yarchoan, Adam C Yopp, Gonzalo Sapisochin, David James Pinato, Anjana A Pillai
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatology communications 8 (6) (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine 30 (4) (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine (2024)
Josep M Llovet, Roser Pinyol, Mark Yarchoan, Amit G Singal, Thomas U Marron, Myron E Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S Finn
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature reviews. Clinical oncology (2024)
Amit G Singal, Mark Yarchoan, Adam C Yopp, Gonzalo Sapisochin, David James Pinato, Anjana A Pillai
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatology communications 8 (6) (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine 30 (4) (2024)
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane Tsukamoto Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth D Thompson, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature medicine 30 (4) (2024)
Shuming Zhang, Atul Deshpande, Babita K Verma, Hanwen Wang, Haoyang Mi, Long Yuan, Won Jin Ho, Elizabeth D Thompson, Qingfeng Zhu, Robert A Anders, Mark Yarchoan, Luciane Tsukamoto Kagohara, Elana J Fertig, Aleksander S Popel
Integration of Clinical Trial Spatial Multi-omics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer research (2024)
Shuming Zhang, Atul Deshpande, Babita K Verma, Hanwen Wang, Haoyang Mi, Long Yuan, Won Jin Ho, Elizabeth D Thompson, Qingfeng Zhu, Robert A Anders, Mark Yarchoan, Luciane Tsukamoto Kagohara, Elana J Fertig, Aleksander S Popel
Integration of Clinical Trial Spatial Multi-omics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer research (2024)
Josep M Llovet, Roser Pinyol, Mark Yarchoan, Amit G Singal, Thomas U Marron, Myron E Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S Finn
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature reviews. Clinical oncology 21 (4) (2024)
Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith, Robert A Anders, Kiyoko Oshima, Amy K Kim, Jacqueline Laurin, Kelly J Lafaro, Christopher R Shubert, William R Burns, Jin He, Richard Andrew Burkhart, Benjamin Philosophe, Jeffrey Meyer, Robert P Liddell, Christos S Georgiades, Kelvin Hong, Won Jin Ho, Nilofer S Azad, Alexandra T Strauss, Mark Yarchoan
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC. Cancer research communications 4 (8) (2024)
Amit G Singal, Mark Yarchoan, Adam C Yopp, Gonzalo Sapisochin, David James Pinato, Anjana A Pillai
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatology communications 8 (6) (2024)
Shuming Zhang, Atul Deshpande, Babita K Verma, Hanwen Wang, Haoyang Mi, Long Yuan, Won Jin Ho, Elizabeth D Thompson, Qingfeng Zhu, Robert A Anders, Mark Yarchoan, Luciane Tsukamoto Kagohara, Elana J Fertig, Aleksander S Popel
Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer research 84 (16) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Shuming Zhang, Atul Deshpande, Babita K Verma, Hanwen Wang, Haoyang Mi, Long Yuan, Won Jin Ho, Elizabeth D Thompson, Qingfeng Zhu, Robert A Anders, Mark Yarchoan, Luciane Tsukamoto Kagohara, Elana J Fertig, Aleksander S Popel
Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer research 84 (16) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Amit G Singal, Mark Yarchoan, Adam C Yopp, Gonzalo Sapisochin, David James Pinato, Anjana A Pillai
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatology communications 8 (6) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith, Robert A Anders, Kiyoko Oshima, Amy K Kim, Jacqueline Laurin, Kelly J Lafaro, Christopher R Shubert, William R Burns, Jin He, Richard Andrew Burkhart, Benjamin Philosophe, Jeffrey Meyer, Robert P Liddell, Christos S Georgiades, Kelvin Hong, Won Jin Ho, Nilofer S Azad, Alexandra T Strauss, Mark Yarchoan
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC. Cancer research communications 4 (8) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Daniel J Zabransky, Mark Yarchoan, Won Jin Ho
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy. Hepatology (Baltimore, Md.) 79 (4) (2023)
Daniel J Zabransky, Mark Yarchoan, Won Jin Ho
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy. Hepatology (Baltimore, Md.) (2023)
Daniel J Zabransky, Mark Yarchoan, Won Jin Ho
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy. Hepatology (Baltimore, Md.) 79 (4) (2023)
Stephanie L Alden, Mir Lim, Chester Kao, Daniel H Shu, Amit G Singal, Anne M Noonan, Paige Griffith, Nilofer S Azad, Won Jin Ho, Ihab R Kamel, Mark Yarchoan, David Hsiehchen
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer research communications 3 (7) (2023)
Daniel J Zabransky, Mark Yarchoan, Won Jin Ho
Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy. Hepatology (Baltimore, Md.) 79 (4) (2023)
Daniel H Shu, Won Jin Ho, Luciane Tsukamoto Kagohara, Alexander A Girgis, Sarah M Shin, Ludmila V Danilova, Jae W Lee, Dimitrios N Sidiropoulos, Sarah Mitchell, Kabeer Munjal, Kathryn Howe, Kayla J Bendinelli, Hanfei Qi, Guanglan Mo, Janelle Montagne, James M Leatherman, Tamara Y Lopez-Vidal, Qingfeng Zhu, Amanda L Huff, Xuan Yuan, Alexei Hernandez, Erin M Coyne, Neeha Zaidi, Daniel J Zabransky, Logan L Engle, Aleksandra Ogurtsova, Nilofer S Azad, Daniel Laheru, Jennifer N Durham, Hao Wang, Robert Anders, Elizabeth D Thompson, Elana J Fertig, Mark Yarchoan
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade. bioRxiv : the preprint server for biology (2023)
Tim F Greten, Augusto Villanueva, Firouzeh Korangy, Benjamin Ruf, Mark Yarchoan, Lichun Ma, Eytan Ruppin, Xin W Wang
Biomarkers for immunotherapy of hepatocellular carcinoma. Nature reviews. Clinical oncology (2023)
Amol Gupta, Jane Zorzi, Won Jin Ho, Nilofer S Azad, Nilofer Saba Azad, Paige Griffith, Doan Dao, Amy Kim, Benjamin Philosophe, Christos Georgiades, Ihab R Kamel, Richard Burkhart, Robert Liddell, Kelvin Hong, Christopher Shubert, Kelly Lafaro, Jeffrey Meyer, Robert Anders, William Burns, Mark Yarchoan
Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis. Healthcare (Basel, Switzerland) 11 (18) (2023)
Amanda N Ruggieri, Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, Helen X Chen, Brian M Olson, Chrystal M Paulos, Bassel F El-Rayes, Shishir K Maithel, Nilofer S Azad, Gregory B Lesinski
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta, Nilo Azad, Ahmet Gurakar, Ming-Tseh Lin, Dung T Le, Daniel C Brennan, Elizabeth M Jaffee, Katherine Bever
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. Current oncology (Toronto, Ont.) 30 (1) (2022)
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta, Nilo Azad, Ahmet Gurakar, Ming-Tseh Lin, Dung T Le, Daniel C Brennan, Elizabeth M Jaffee, Katherine Bever
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. Current oncology (Toronto, Ont.) 30 (1) (2022)
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta, Nilo Azad, Ahmet Gurakar, Ming-Tseh Lin, Dung T Le, Daniel C Brennan, Elizabeth M Jaffee, Katherine Bever
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. Current oncology (Toronto, Ont.) 30 (1) (2022)
Kabir Mody, Prerna Jain, Sherif M El-Refai, Nilofer S Azad, Daniel J Zabransky, Nilofer S Azad, Rachna T Shroff, Robin Kate Kelley, Anthony B El-Khoueiry, Adam J Hockenberry, Denise Lau, Gregory B Lesinski, Mark Yarchoan
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO precision oncology 6 (2022)
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta, Nilo Azad, Ahmet Gurakar, Ming-Tseh Lin, Dung T Le, Daniel C Brennan, Elizabeth M Jaffee, Katherine Bever
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. Current oncology (Toronto, Ont.) 30 (1) (2022)
Krista Y Chen, Aleksandra Popovic, David Hsiehchen, Marina Baretti, Paige Griffith, Ranjan Bista, Azarakhsh Baghdadi, Ihab R Kamel, Sanford M Simon, Rachael D Migler, Mark Yarchoan
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers 14 (21) (2022)
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta, Nilo Azad, Ahmet Gurakar, Ming-Tseh Lin, Dung T Le, Daniel C Brennan, Elizabeth M Jaffee, Katherine Bever
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. Current oncology (Toronto, Ont.) 30 (1) (2022)
Lauren Dennison, Aditya A Mohan, Mark Yarchoan
Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. Current oncology reports 23 (2) (2021)
Mark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, Anna K Ferguson, Jennifer N Durham, Robert A Anders, Elizabeth D Thompson, Noah S Rozich, Dwayne L Thomas, Julie M Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus-Acosta, Dung T Le, Adrian G Murphy, Daniel Laheru, Ross C Donehower, Elizabeth M Jaffee, Lei Zheng, Nilofer S Azad
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer medicine 9 (4) (2019)
Mark Yarchoan, Aditya A Mohan, Lauren Dennison, Teena Vithayathil, Amanda Ruggieri, Gregory B Lesinski, Todd D Armstrong, Nilofer S Azad, Elizabeth D Thompson
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. PloS one 14 (10) (2019)